Clinical Efficacy of Stopping Oral Antibiotics When Symptoms Stop, Compared to 'Finishing the Course'
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age1-17
SponsorMurdoch Childrens Research Institute
About this trial
The aim of the StopStop@HITH study is to see if stopping antibiotics when symptoms stop is as good as finishing the course of antibiotics. The study will enrol children at the Royal Children's Hospital who are prescribed oral antibiotics after completing a course of intravenous (IV) antibiotics for the treatment of cellulitis, urinary tract infection (UTI), lower respiratory tract infection (LRTI) and lymphadenitis.
The aims of the study are:
* To determine if oral antibiotics can be safely stopped once symptoms stop in children with cellulitis (who have completed a course of IV antibiotics). * To assess feasibility of a larger study of other common infections across multiple hospitals.
The participants parent/guardian will complete a daily symptom tracker for the duration of the prescribed oral antibiotic course and attend a telehealth appointment with the study team once the participants symptoms have resolved. There are additional follow up surveys at day 14, day 28 and day 180.
Eligibility criteria
Qualifiers
Between the ages of ≥ 1 years and ≤ 17 years at enrolment
Diagnosis of cellulitis, urinary tract infection (UTI), lower respiratory tract infection (LRTI) or lymphadenitis
Prescription of oral antibiotics as a switch from IV antibiotics
Disqualifiers
Clinician determined need for >10-day oral antibiotic course
Child with immunosuppression (e.g. as a result of cancer treatment)
Second episode of same bacterial infection within the last 28 days
Child is unable to take oral antibiotics
Trial design
Treatments tested in this trial
- Antibiotics for duration of symptoms
- Antibiotics for duration of prescribed course
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Murdoch Childrens Research Institute
Lead sponsor
Royal Children's Hospital
Collaborator
Source ClinicalTrials.gov